Document includes Islet Sciences’ Science, company highlights, Why The Islet Sciences Solution?, business model, existing infrastructure, etc.

1. Islet Sciences
COMPANY HIGHLIGHTS
Led by John Steel, Chairman, Interim CEO, Chief Scientfic Officer Jonathan Lakey, Ph.D., a renowned diabetes expert and co-
developer of the Edmonton Protocol and George J. Todaro, MD, Islet Sciences, Inc. is a development-stage biotechnology company
with patented and proprietary technologies focused on transplantation therapy for people with insulin-dependent diabetes.
Urgent Need. Diabetes is a devastating, lifelong condition that affects people of every age, race, and nationality, including
approximately 21 million Americans. It is the leading cause of kidney failure, blindness in adults, and amputations unrelated to injury.
More than half of Americans will have diabetes or be prediabetic by 2020 at a cost to the U.S. health care system of $3.35 trillion if
current trends go on unabated
Proof Of Concept. Islet Sciences’ therapeutic approach builds on 2001 research breakthroughs at the University of Alberta -
Edmonton. A team of Edmonton scientists led by Drs. James Shapiro and Jonathan Lakey developed methods for harvesting
pancreatic islet cells and then transplanting these insulin¬producing cells to patients. The Edmonton Protocol allowed the majority of
patients treated to become insulin-independent. However, there are two major scientific and medical challenges with the Edmonton
Protocol: [1] an inadequate supply of human donor tissue; and [2] the need for continuous immunosuppressive drugs to prevent
rejection of the transplanted islet cells.
Solution. The Company's technology comprises a proprietary microencapsulation process designed to reduce, and possibly eliminate,
the need for continuous immunosuppressive drugs. In pre-clinical primate studies, subjects continued to exhibit improved glycemic
control over a six-month period with transient immunosuppressive therapy to prevent rejection of the transplanted insulin-producing
islets.
High-Profile Collaborations. The Company has several important collaborations, including the National Institutes of Health (NIH),
Neostem, Diakine, University of Oxford, UK, University of Virginia, and the University of California and Progenitor Cell Therapy.
Significant Business Opportunity. Islet Sciences will initially focus on diabetic patients requiring kidney transplants as a result of
end stage renal disease brought on by their diabetes. There are 100,000 new cases of end stage renal disease reported each year that
result in approximately 16,000 kidney transplants annually. It is estimated that 40% of the transplant patients are diabetics who exhibit
better graft and patient survival if they receive islet cells at the same time as they receive their new kidneys. In addition, of the
200,000 patients currently living with kidney transplants, many could benefit from islet replacement therapy. If a total of 5,000 to
7,500 patients per year from either of these groups were to receive Islet Sciences’ transplantation therapy, at an average dosing price
of $100,000, Islet Sciences’ annual revenue opportunity could be $500 million to $750 million in the US market alone.
1"National Diabetes Fact Sheet, United States 2005, CDC" at www.cdc.diabetes.gov
Business Description. Islet Sciences, Inc. is a development-stage biotechnology company with patented technologies focused on
transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for
the culturing, isolation, maturation, and immuno-protection (microencapsulation) of islet cells. Islet Sciences’ mission includes the
introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. The traditional
treatment for Type 1 diabetes involves daily "fingerstick" monitoring of blood glucose levels throughout the day, with multiple daily
injections of insulin or its continuous infusion. This approach does not cure the disease nor its complications, and often is associated
with poor blood glucose control, which has a long-term deleterious effect on major organs.
Industry Background. According to the International Diabetes Foundation (IDF), an estimated 300 million people worldwide have
diabetes, 25 million in the US alone. Over 10 million people use insulin worldwide. According to the World Health Organization
(WHO), diabetes is the fourth-leading cause of death in developed countries. Worldwide, there are an estimated 3.2 million diabetes-
related deaths every year. In the United States, in any given year between 1.5 and 2.0 million people suffer from insulin¬dependent,
Type 1 diabetes. Between 16 million and 19 million people are estimated to have Type 2 diabetes. The cost of diabetes is enormous.
According to the IDF, as much as 10% of the world's healthcare budget is spent on diabetes-related maladies. Predominantly because
of complications, diabetes represents over $200 billion in U.S. healthcare costs.

2. Current Therapies. Individuals suffering from insulin-dependent, Type 1 diabetes, suffer from an autoimmune disorder where the
immune system attacks and destroys insulin-producing islet cells of the pancreas. These cells are created shortly after birth and cannot
repair themselves once damaged. Patients need multiple daily injections of insulin and have to perform glucose monitoring via
"fingerstick" blood sampling many times each day. Obviously, many patients fail to properly adhere to these onerous demands, and
even strict adherence does not guarantee protection from long-term complications like kidney failure, blindness, heart attack, stroke,
amputations, etc. By normalizing blood glucose levels, a successful Islet Sciences product would avert the long-term complications
mentioned above, and eliminate the need for such constant injections and monitoring.
Islet Sciences’ Science
The Edmonton Protocol, a Proof Of Concept
A research team at the University of Alberta (that was led by Islet Sciences' CSO Dr. Jonathan Lakey) managed to reverse diabetes in
scores of patients by transplanting them with human pancreatic islet cells. By June 2002, the "Edmonton Protocol" had been
performed on more than 130 patients -and 85% of the original patients remained insulin-free for one year or more following the
transplant. The Edmonton Protocol is recognized worldwide as one of the most significant advances in diabetes treatment.
Hurdles Overcome By Islet Sciences’ Approach
The Edmonton Protocol faces three major obstacles that prevent it from helping a broader group of patients with insulin-dependent
diabetes: [1] the inadequate supply of human donor tissue; [2] the need for continuous immuno-suppressive drugs to prevent rejection
of the transplanted human islet cells. Islet Sciences’ scientific approach could overcome these three obstacles; [3] the Edmonton
Protocol is a difficult procedure. Islet Sciences' developmental products use pathogen-free porcine islets, which are in abundant
supply. In addition, the Company encapsulates islets to minimize immune rejection and the need for immunosuppressive therapy.
When successfully proven, this scientific approach may allow transplantation to become a preferred therapy for insulin¬dependent
diabetes.
Islet Sciences is developing a vialed suspension of microencapsulated porcine islets for implantation into the abdominal cavity using a
minimally invasive procedure. Microencapsulation involves surrounding islet cells with formulations of a highly biocompatible, ultra-
pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coating allows insulin, glucose, oxygen and
other nutrients to diffuse freely, while blocking antibodies and reducing the patient's immune response to the implanted islet cells. Islet
Sciences-PTM will provide physiologic and self-regulating blood glucose control, thus reducing the need for insulin injections or
infusions and constant blood glucose monitoring. In addition, there exists an opportunity to mitigate the long-term complications
associated with the disease.
Antibodies Blocked
Alginate Coating
Glucose, Oxygen and Poly-amino Acid Membrane
Other Nutrients Diffuse
Freely Alginate Core (liquefied)
Islet
Lymphocyters Blocked
Insulin Diffuses Freely

3. Porcine Cells -A Mission-Critical Supply Agreement
The use of porcine-derived biologic materials is established in human therapeutics, including insulin and heart valves. FDA requires
that porcine islets used in clinical studies for transplantation in humans come from designated pathogen free (DPF) pigs raised in a
U.S. Department of Agriculture certified facility. Progenitor cell therapy is our GcMP manufacturing partner through
commercialization and marketing. PCT has unique expertise in FDA required cell processing.
ENCAPSULATED ISLET CELLS
Patented Technologies
Islet Sciences’ patent estate is focused on enabling and protecting the first commercially viable cure for Type 1 diabetes. The
Company has delivered, and continues to develop, a wide range of intellectual property advances to meet this goal. The advances
detail improved methods and devices for the production of viable microencapsulated cells for human transplantation. These
innovations cover culturing, isolation, maturation and encapsulation of pancreatic islets. Internally, Islet Sciences’ scientists have
further refined such techniques into what we believe to be the first commercial practical transplantation treatment for diabetes.
Recognizing that multiple technologies will be needed to successfully commercialize an encapsulation product, our staff actively
invents in other vital areas, including: 1) accurate dosing of a patient via improved quantification methods of functioning islets, 2)
biocompatibility advances designed to improve patient acceptance of the capsules, 3) co-encapsulation of agents to enhance islet
survival and function, 4) modifiable alginate polymers and polyelectrolyte compositions designed to improve; molecular diffusion
properties, capsule integrity, survivability, and functionality, 5) new controlled delivery systems for varied therapeutic applications,
including co-encapsulation, and, 6) innovative outer layer compositions allowing better adhesion properties and placement
dependability of microcapsules.
Islet Sciences believes these technologies represent state-of-the-art methods for the commercial production of vastly improved
microencapsulated islet cells, and thereby, the first potential transplantation therapy for diabetes patients worldwide. Finally, the
uniqueness of our capsules, and their compatibility with various cell types, may expand our probable markets into transplantation
opportunities beyond diabetes.
Development Strategy: Xenotransplantation
Xenotransplantation is the removal of an organ or tissue from one species of animal and transplanting it to a member of another
species. For example, porcine heart valves have long been successfully implanted in humans, and this is now considered routine. Islet
Sciences’ studies utilize encapsulated porcine islet cells and will be the basis of the company's product, Islet Sciences-P™.
Why The Islet Sciences Solution?
Non-Encapsulated Human Islet Approach Porcine Islet Approach
 Limited Supply  Supply Not Limited; Controllable
 Origin and Timing Uncertain  Origin Known, Planning Possible
 Chronic Immunosuppression Therapies Necessary  Reduced or No Immunosuppression Required
 More Invasive  Minimally Invasive
 Islets Are Less Pure, Less Stable  Preparations of Greater Purity, Higher Quality, More Stable

4. Business Model
Strategic Focus
In capitalizing on its proprietary intellectual property, Islet Sciences has focused on three major diabetes market segments. The initial,
primary emphasis is on high-risk patient populations. This includes diabetic kidney transplant patients, as well as patients with poorly
controlled, complicated instances of Type 1 diabetes. Diabetes is the leading cause of End Stage Renal Disease, or ESRD, accounting
for an estimated 44% of new cases each year. The patient population (and prospective business opportunity) is expanding, because
there are approximately 100,000 new cases of ESRD every year, adding up to greater than $4 billion in annual dialysis outlays.
According to the National Kidney and Urologic Disease Information Clearinghouse, the relationship between diabetes and ESRD is
reason enough to justify accelerated research toward new early-stage diabetes therapies. It is estimated that as many as 40% of Type 1
diabetes patients develop ESRD by age 50. In the absence of adequate and timely treatment by dialysis or transplantation, these
patients die.
Diabetes and Kidney Transplants
Islet Sciences’ immediate focus will target kidney transplant recipients as a "gateway" clinical application. Uncontrolled diabetes often
results in severe damage to a victim's kidneys. When the patient receives a kidney transplant, the same forces at work that destroyed
the original kidneys will soon start to work on the transplanted kidney(s), unless something is done to control the diabetic condition.
Islet Sciences Therapy
Islet Sciences’ technology involves the implantation of insulin-producing islets in the peritoneum using a minimally invasive
procedure.
Medical research indicates that there is an increase in the survival rate of diabetics with kidney transplants if they also receive a
pancreas transplant. Unfortunately, there is an extreme shortage of pancreas donors relative to the number of kidney transplants. In
2004, for instance, there were only 1,500 pancreas transplants performed vs. more than 15,000 kidney transplants. While available
pancreas organs are in short supply, they offer an insight into the benefit of islet transplantation therapy, which would serve as a
virtual proxy for pancreatic transplantation. A pancreas transplant in conjunction with a kidney transplant results in a significantly
higher patient survival rate. However, this is not feasible because of the limited supply of donor pancreases, Islets are more available,
as well as more easily administered.
It is clear to many that islet transplantation therapy can help reduce the long-term complications arising from diabetes, and reduce
health-care costs. The potential advantages for targeting this market include some significant patient benefits: better diabetes control;
improved quality of life; improved kidney graft survival; and improved survival. Islet Sciences management sees significant revenue
potential for Islet Sciences-PTM in the kidney transplant market. In the US market, Islet Sciences believes that Orphan status (a
government program that rewards the development of therapies for under-treated patient populations via tax breaks, expedited FDA
reviews, etc.) may be obtainable. Finally, the Company is confident that our products will be covered by health insurance, including
Medicare and private insurers.
old
The revenue potential for Islet Sciences is significant for this relatively small subset of diabetes patients. The prospective pricing is
currently unknown, but may range between $60,000 and $120,000 per procedure, at an estimated $100,000 per dose based on current
all graft reimbursement per patient, treatment of 5,000 patients represents $500 million in annual revenue potential. The annual
revenue opportunity could be a multiple of this figure, given the large number of prospective candidates for this therapy who are in the
pool of more than 150,000 living with kidney transplants. With expanded market acceptance and greater usage, an increased dosage
cost could yield even higher annual revenues.

5. Beyond ESRD and kidney transplant patients, secondary indications targeted by Islet Sciences may include more typical patients with
insulin-treated Type 1 diabetes. Other potential candidates for treatment include the two to four million people who are late-stage,
Type 2 insulin-dependent diabetics.
Clinical Approach
The microencapsulation of insulin-producing porcine islet tissues protects them from immune system rejection, while the use of a
minimally invasive procedure to implant the insulin-producing islets into the peritoneum enhances the safety profile of human testing.
Utilizing these advances, Islet Sciences has a clear, clinical strategy beginning with IAk patients and expanding into other difficult to
control diabetes states.
Existing Infrastructure
There are currently fifteen US domiciled clinical sights and at least another twenty globally pursuing versions of the 'Edmonton
Protocol'. As outlined previously the challenges of human islet transplantation are numerous preventing any commercially viable
economic or therapeutic opportunity.
Importantly, the medical centers currently pursuing Islet transplantation would be ideal for commercialisation and efficient
distribution of Islet’s first product and patient cohort.
Islet Sciences has an alliance with Progenitor Cell Therapy, a divisionof Neostem, to provide FDA required clinical grade product
continuously through commercialization and marketing the typical middleman distribution and marketing function
could be eliminated. There are tens of thousand of IAK patients as patients in the various domestic centers; PCT
produced product could be continuously shipped to sights based on significant demand and need. The National
Institutes of health, NIH -underwrites much of the science and new therapeutics application at these designated
medical sights for clinical islet transplantion, and has guidance that additional grant funding will be mad available
for product in the clinic for T1Diabets
Currently the hospitals are performing human islet transplantation on an 'ad hoc' basis based on availability proper donor situation
with out Gcmp production.
Based on the anticipated IAK (?) therapeutic demand of 10,000 persons annually this would require 2 procedures daily, based on the
out patient minimally available procedure per sight.
Manufacturing
Progenitor Cell Therapy is our GcMP manufacturing partner through commercialization and marketing. PCT has unique expertise in
FDA required cell processing. Progenitor Cell Therapy (PCT) is a client-based cell therapy services company that supports the
development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services
that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and
consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and
storage, product manufacturing, distribution and transportation.
Dr. Robert A. Preti, Ph.D. is PCT's Co-Founder, President, and Chief Scientific Officer of Progenitor Cell Therapy,, and a member
of NeoStem’s Board of Managers. He has held these positions since March 1999. Through his administrative duties, Dr. Preti has
overseen the growth of PCT from its inception to the world’s leading commercial cell therapy company.
Previous positions held by Dr. Preti include Scientific and Laboratory Director of Hackensack University Medical Center's stem cell
processing and research laboratory and Scientific Director of the Clinical Services Division at the New York Blood Center.
He is one of the country's leading authorities on cell engineering, advanced cell and gene therapy manufacturing, testing and delivery,
and regulatory aspects relating to the cell therapy and regenerative medicine industry. He has been the principal investigator for a
number of clinical trials relating to the clinical testing of cellular therapies. He is a frequently invited speaker at international and
national symposia and conferences, addressing a wide range of topics within his expertise in the clinical development programs for
cellular therapies, including the business, financial, logistic, and manufacturing, product development, testing, quality, and regulatory
aspects of successful commercialization.

6. Revenue Model
Assuming that ISLT begins its initial patient population proposed in the IND and begins wider distribution into the fifteen diabetes
centers and assuming a roll out of one thousand patients to, five thousand to, ten thousand and down the road, penetration into other
complicated diabetes patients starting in 2016.
And using the comparator of islet transplantation cost dynamic currently reimbursed for Pancreatitis of one hundred thousand per
procedure, the chart below indicates the potential for significant revenue growth.
$2,500,000,000
$2,000,000,000
$1,500,000,000
$1,000,000,000
$500,000,000
$0
1,000 5,000 10,000 15,000 20,000
2014 2015 2016 2017 2018
Per Procedure

7. Management and Board of Directors
George J. Todaro, MD
A renowned research scientist and medical doctor, Dr. Todaro co-authored the groundbreaking “Oncogene Theory” while at the
National Institute of Health (NIH) in Bethesda, Maryland in1969. The “Oncogene Theory” would became one of the foundations for
future cancer research. In the early 90s, as scientific director at Seattle-based PathoGenesis, he developed a treatment that has saved
the lives of countless cystic fibrosis patients. And, more recently, his focus has turned to biotechnology, where he is working to find
ways to increase the world’s food supply. Todaro can also add to his list of accomplishments that he was elected to the National
Academy of Sciences, was a professor and department head at the University of Washington, holds over 20 patents, and was named
one of the Ten Outstanding Young Men of America in 1970.
Joel D. Perlin
Joel Perlin can be considered a veteran when it comes to the understanding and successful management of Type 1 Juvenile Diabetes.
He was diagnosed with the disease in early 1965 in Southern California. His doctors at that time knew little of how to live with and
successfully manage the disease. Mr. Perlin determined at that time the potential benefits associated with maintaining near normal
blood sugar levels to prevent complications. It was more than 20 years later this fact was established by The Diabetes Control and
Complications Trial (DCCT). Mr. Perlin has participated for more than four decades in many of the technological advances including
Insulin Pump therapy since 1983, Continuous Glucose Monitoring since 2006, along with the advances achieved with current insulin
therapy and continuous blood sugar finger testing. His knowledge and practice of living successfully with Type 1 Juvenile Diabetes
has long been a benefit to many other diabetics. Professionally, Mr. Perlin is a renowned numismatist and recognized expert in the
international physical gold coin trade. Since graduating from San Diego State in1969, Mr. Perlin has combined his unique skills and
knowledge with keen insight into the economic and financial factors affecting the precious metals trade. This business expertise has
resulted in highly successful and lucrative gold investment accounts for his clients who have consulted with him in financial affairs in
La Jolla, CA, for more than 40 years.
John Steel, Chairman, Interim CEO
Mr. John Steel is the President & CEO of Islet Sciences. Mr. Steel brings over twenty years of senior management and investment
experience in the healthcare services and biotechnology sector. In 1998, Mr. Steel founded MicroIslet, the firm that pioneered and
developed the technology that comprises Islet Sciences, and served as its Chairman and Chief Executive Office from September 1998
to 2002. From January 1996 to December 1997, Mr. Steel was Chief Executive Officer of AKESIS Pharmaceuticals, Inc., a company
that developed a patented treatment for insulin resistance for Type II diabetes. From January 1987 to June 1990, Mr. Steel served as
the Vice President of Defined Benefit Inc., a company he founded in 1986 that provided financial services to health care professionals.
After Defined Benefit Inc., Mr. Steel was an active investor and consultant within numerous areas including early-stage biotechnology
and device companies through Steel Management. Mr. Steel himself is diagnosed with Type 1 Juvenile Diabetes and is actively
involved in fund raising for various diabetes research-related charities. Mr. Steel has recently chaired panels regarding the future of
diabetes for the California Insurance Commissioner. Mr. Steel is also a noted speaker on the topic of diabetes - including its
management, economics, and future opportunities for improvement in therapeutic modalities. Mr. Steel received his M.B.A. degree
with an emphasis in finance from the University of Southern California and a Bachelor of Arts degree from Dartmouth College.
International Scientific Advisory Board
Chair - Dr. Jonathan Lakey, PhD - MSM
Dr. Jonathan Lakey has had a long history in cell and tissue transplantation with a focus on diabetes and islet transplantation. He
graduated from the University of Alberta (BSc, MSc, PhD) and received postdoctoral training in Indianapolis and Seattle before
returning to establish his research program at the University of Alberta. He is a former Director of the Comprehensive Tissue Bank.
His contributions and partnership with Dr. James Shapiro led towards the improvement of islet isolation techniques and the
development of the “Edmonton Protocol” for patients with Type 1 diabetes, a recognized major advancement in the treatment of
diabetes. He has been awarded research grants and awards for diabetes and transplantation research from the Alberta Heritage
Foundation for Medical Research (AHFMR), Canadian Diabetes Association and the Juvenile Diabetes Foundation International
(JDFI). Dr. Lakey is widely sought after as a speaker in the field of diabetes islet transplantation and regulatory standards of cell and
tissue transplantation. He has been widely published with over 250 referred scientific papers, 26 book chapters, submitted over 500
scientific abstracts, and has recently published a technical book on islet isolation. Among his proudest achievements, Dr. Lakey and
his team have successfully trained over 40 islet transplant centers worldwide in replicating the Edmonton Protocol, resulting in
diabetic patients being freed from exogenous insulin injections. He sits on editorial boards of several diabetes and transplantation
journals, reviews manuscripts for several journals, and has served as a Councilor for Cell Transplant Society. Currently, Dr. Lakey is
the Director of Research and Associate Professor of Surgery at the University of California, Irvine. He recently accepted the position
of Director of the Clinical Islet Program at the University of California, Irvine.
Paul Johnson, MBChB MD FRCS, President, IPITA

8. Director of Oxford Islet Transplant Programme and Professor of Paediatric Surgery, University of Oxford. Dr. Johnson also currently
serves as President of the International Pancreas and Islet Transplant Association. Paul Johnson qualified in medicine from the
University of Leicester and subsequently trained in General Surgery in Leicester and Derby, followed by higher surgical training in
Paediatric Surgery in Oxford, Melbourne, and Great Ormond Street Hospital in London. Between 1993 and 1996 he was a Research
Fellow in the Department of Surgery at the University of Leicester, where he undertook a project on the Isolation of Human Islets of
Langerhans for Pancreatic Islet Transplantation. This led to a Doctorate of Medicine and started his ongoing interest in the field of
Islet Transplantation for reversing Type 1 Diabetes. He was awarded a Hunterian Professorship from the Royal College of Surgeons of
England for this research in 1998. In 2002, Mr. Johnson was appointed Director of the Islet Transplant Programme in Oxford. He is
currently Chairman of the Research division of British Association of Paediatric Surgeons Research and Clinical Effectiveness
Committee, Founder of the UK Academic Paediatric Surgeons Group and Co-Secretary of the International Pancreas and Islet
Transplantation Association. He is also Clinical Tutor at St. Edmund Hall. He has an active research group and his research interests
include ways of optimizing the current methods used for islet isolation with particular reference to pancreatic structure and
collagenase, and the developmental biology of the pancreas and foregut with particular relevance to the use of adult stem cells as an
alternative source of islet tissue for transplantation. In addition to islet transplantation, his clinical interests include the neonatal and
paediatric pancreas (endocrine and exocrine), as well as other aspects of paediatric surgical gastroenterology.
Steven Paraskevas, MD PhD
Dr. Paraskevas is a transplant surgeon at McGill University Health Centre, specializing in pancreas and kidney transplantation.
Originally from Winnipeg, Dr. Paraskevas obtained a BA in Biology at Harvard University in 1988, and obtained his MD and
completed General Surgery Residency at McGill. During that time, he also studied mechanisms of cell death in transplanted human
islets, completing a PhD in Experimental Surgery at McGill in 2003. Based on this work, he also earned the Scientific Trainee Award
of the Canadian Diabetes Association in 1997. After residency, he completed a two-year fellowship in abdominal solid-organ
transplantation at the University of Minnesota, where he was also involved in the clinical islet transplant program under Dr. Bernhard
Hering. He returned to McGill in 2002 as Assistant Professor in Surgery, and member of the multi-organ transplant program. He is
currently Director of the Pancreas and Islet Transplant Program and of the Human Islet Isolation Laboratory at McGill. His current
research focuses on mechanisms of cell survival during ischemia and the effect of metabolic and inflammatory stress on engraftment
of human islets. He is a Councillor-at-large of the Canadian Society of Transplantation and Chair of the Cell Transplant Committee of
the American Society of Transplant Surgeons.
Miguel Riella, MD, PhD
Dr. Riella is a graduated of Federal University of Parana in Curitiba Brazil and has undertaken his post-graduate training in the United
States, first in Internal Medicine, Residency at Mount Sinai Hospital in NYC and then Research Renal Fellowship at the University of
Washington in Seattle, USA. His main interest has been in dialysis, particularly peritoneal dialysis and nutrition in uremia. More
recently his research work has been concentrated in the relationship of inflammation, uremia, nutrition and cardiovascular
complications. As part of his new RDH Research Center (Renal, Diabetes and Hypertension Research Center) he has recently
established the Islet Cell Laboratory for cell transplant in diabetic patients. Dr. Riella has published several books in Portuguese and
Spanish language in the area of Nephrology and Nutrition. He is a member of the executive committee of the International Society of
Nephrology and is the Chairman of the new ISN-Interventional Nephrology Committee. He is a member of the editorial board of
several medical journals, is the Associate Editor of Hemodialysis International and the co-editor of the Portuguese version of Kidney
International.
Jerry L. Nadler, MD
Dr. Nadler is Professor and Chairman of Internal Medicine, the Harry H. Mansbach Endowed Chair in Internal Medicine and Director
of the Strelitz Diabetes Center at Eastern Virginia Medical School. Dr. Nadler is also the Scientific Founder of Diakine, a seed stage
company developing therapies for type 1 and type 2 diabetes and related complications. Dr. Nadler is also a Pfizer Visiting Professor
in Diabetes. Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the director of the National
Institutes of Health Diabetes Institute. Dr. Nadler was also the Associate Director of the NIH-funded Diabetes Endocrinology
Research Center at the University of Virginia. Dr. Nadler has research funding from the Juvenile Diabetes Foundation, The Ella
Fitzgerald Charitable Foundation and the Iacocca Foundation. He is a standing member of the ADA and NIH grant review
committees.